FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204160185> ?p ?o ?g. }

• W3204160185 endingPage "1617" @default.
• W3204160185 startingPage "1609" @default.
• W3204160185 abstract "Treatment options for patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia are scarce. The synergistic antitumour effect of immunotherapy and antiangiogenic drugs has been shown in many solid tumours. This phase 2 trial evaluated the activity and safety of camrelizumab (PD-1 inhibitor) plus apatinib (VEGF receptor inhibitor) in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia.This was a single-arm, open-label, phase 2 trial, done at a single tertiary health-care centre in Beijing, China. Women (18-70 years) with high-risk (International Federation of Gynecology and Obstetrics score ≥7) chemorefractory or relapsed gestational trophoblastic neoplasia who had received at least two lines of previously unsuccessful multidrug chemotherapy regimens and had an Eastern Cooperative Oncology Group performance status of 0-2 were eligible for inclusion. Patients received 4-week cycles of intravenous camrelizumab 200 mg every 2 weeks plus oral apatinib 250 mg once per day until disease progression or unacceptable toxicity. The primary endpoint was objective response rate assessed according to serum human chorionic gonadotrophin concentration. Activity and safety were analysed in all patients who received at least one dose of study drug. The study is ongoing, but recruitment is complete. The study is registered with ClinicalTrials.gov, NCT04047017.Between Aug 7, 2019, and March 18, 2020, 20 patients enrolled; 19 (95%) were diagnosed with choriocarcinoma and one (5%) had placental site trophoblastic tumour. The median follow-up duration was 18·5 months (IQR 14·6-20·9). The objective response rate was 55% (95% CI 32-77); ten (50%; 95% CI 27-73) patients had complete response. The most common grade 3 treatment-related adverse events were hypertension (five [25%] patients), rash (four [20%] patients), neutropenia (two [10%]), leukocytopenia (two [10%]), and aspartate aminotransferase increase (two [10%]). One patient had a treatment-related serious adverse event (aspartate aminotransferase 19-times higher than the upper limit of normal). No grade 4 or 5 treatment-related adverse events were reported.Camrelizumab plus apatinib showed promising antitumour activity and acceptable toxicity and could be a salvage therapy option for the treatment of high-risk chemorefractory or relapsed gestational trophoblastic neoplasia. Immune checkpoint inhibitors combined with chemotherapy for heavily-treated patients and upfront use of camrelizumab plus apatinib for patients with high-risk gestational trophoblastic neoplasia are under investigation in phase 2 trials.National Natural Science Foundation of China, Jiangsu Hengrui Pharmaceuticals." @default.
• W3204160185 created "2021-10-11" @default.
• W3204160185 creator A5024792434 @default.
• W3204160185 creator A5045779690 @default.
• W3204160185 creator A5047053745 @default.
• W3204160185 creator A5047153226 @default.
• W3204160185 creator A5050026660 @default.
• W3204160185 creator A5053574015 @default.
• W3204160185 creator A5058831920 @default.
• W3204160185 creator A5069951259 @default.
• W3204160185 creator A5087435355 @default.
• W3204160185 creator A5088213605 @default.
• W3204160185 date "2021-11-01" @default.
• W3204160185 modified "2023-10-16" @default.
• W3204160185 title "Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial" @default.
• W3204160185 cites W1574212147 @default.
• W3204160185 cites W1983271820 @default.
• W3204160185 cites W2046240354 @default.
• W3204160185 cites W2148665128 @default.
• W3204160185 cites W2168491140 @default.
• W3204160185 cites W2171891459 @default.
• W3204160185 cites W2567732912 @default.
• W3204160185 cites W2609748267 @default.
• W3204160185 cites W2755035474 @default.
• W3204160185 cites W2769809456 @default.
• W3204160185 cites W2789258259 @default.
• W3204160185 cites W2793379851 @default.
• W3204160185 cites W2897612290 @default.
• W3204160185 cites W2913818218 @default.
• W3204160185 cites W2942215178 @default.
• W3204160185 cites W2942518262 @default.
• W3204160185 cites W2964767797 @default.
• W3204160185 cites W2986605649 @default.
• W3204160185 cites W3005002419 @default.
• W3204160185 cites W3025003676 @default.
• W3204160185 cites W3027448020 @default.
• W3204160185 cites W3032571309 @default.
• W3204160185 cites W3044901904 @default.
• W3204160185 cites W3093932148 @default.
• W3204160185 cites W3095089286 @default.
• W3204160185 cites W3177205810 @default.
• W3204160185 cites W4254790161 @default.
• W3204160185 doi "https://doi.org/10.1016/s1470-2045(21)00460-5" @default.
• W3204160185 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34624252" @default.
• W3204160185 hasPublicationYear "2021" @default.
• W3204160185 type Work @default.
• W3204160185 sameAs 3204160185 @default.
• W3204160185 citedByCount "35" @default.
• W3204160185 countsByYear W32041601852021 @default.
• W3204160185 countsByYear W32041601852022 @default.
• W3204160185 countsByYear W32041601852023 @default.
• W3204160185 crossrefType "journal-article" @default.
• W3204160185 hasAuthorship W3204160185A5024792434 @default.
• W3204160185 hasAuthorship W3204160185A5045779690 @default.
• W3204160185 hasAuthorship W3204160185A5047053745 @default.
• W3204160185 hasAuthorship W3204160185A5047153226 @default.
• W3204160185 hasAuthorship W3204160185A5050026660 @default.
• W3204160185 hasAuthorship W3204160185A5053574015 @default.
• W3204160185 hasAuthorship W3204160185A5058831920 @default.
• W3204160185 hasAuthorship W3204160185A5069951259 @default.
• W3204160185 hasAuthorship W3204160185A5087435355 @default.
• W3204160185 hasAuthorship W3204160185A5088213605 @default.
• W3204160185 hasConcept C126322002 @default.
• W3204160185 hasConcept C141071460 @default.
• W3204160185 hasConcept C143998085 @default.
• W3204160185 hasConcept C172680121 @default.
• W3204160185 hasConcept C203092338 @default.
• W3204160185 hasConcept C2776571570 @default.
• W3204160185 hasConcept C2776694085 @default.
• W3204160185 hasConcept C2776953305 @default.
• W3204160185 hasConcept C2779234561 @default.
• W3204160185 hasConcept C2780668389 @default.
• W3204160185 hasConcept C2780739268 @default.
• W3204160185 hasConcept C31760486 @default.
• W3204160185 hasConcept C535046627 @default.
• W3204160185 hasConcept C54355233 @default.
• W3204160185 hasConcept C71924100 @default.
• W3204160185 hasConcept C86803240 @default.
• W3204160185 hasConceptScore W3204160185C126322002 @default.
• W3204160185 hasConceptScore W3204160185C141071460 @default.
• W3204160185 hasConceptScore W3204160185C143998085 @default.
• W3204160185 hasConceptScore W3204160185C172680121 @default.
• W3204160185 hasConceptScore W3204160185C203092338 @default.
• W3204160185 hasConceptScore W3204160185C2776571570 @default.
• W3204160185 hasConceptScore W3204160185C2776694085 @default.
• W3204160185 hasConceptScore W3204160185C2776953305 @default.
• W3204160185 hasConceptScore W3204160185C2779234561 @default.
• W3204160185 hasConceptScore W3204160185C2780668389 @default.
• W3204160185 hasConceptScore W3204160185C2780739268 @default.
• W3204160185 hasConceptScore W3204160185C31760486 @default.
• W3204160185 hasConceptScore W3204160185C535046627 @default.
• W3204160185 hasConceptScore W3204160185C54355233 @default.
• W3204160185 hasConceptScore W3204160185C71924100 @default.
• W3204160185 hasConceptScore W3204160185C86803240 @default.
• W3204160185 hasFunder F4320321001 @default.
• W3204160185 hasIssue "11" @default.
• W3204160185 hasLocation W32041601851 @default.
• W3204160185 hasLocation W32041601852 @default.

• next